Director/PDMR Shareholding

RNS Number : 9556V
Arix Bioscience Plc
17 December 2021
 

Arix Bioscience plc

Director/PDMR Shareholdings

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne

2

 

Reason for the notification

 

a)

 

Position/status

 

CEO and General Counsel

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each



Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




1 20.00p

41,666.00


d)

 

Aggregated information




- Aggregated volume

N/A single transaction



- Price

£49,999.20



e)

 

Date of the transaction

 

16 December 2021

f)

 

Place of the transaction

 

London Stock Exchange

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

 Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each



Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




1 19.00p

84,000.00


d)

 

Aggregated information




- Aggregated volume

N/A single transaction



- Price

£99,959.98



e)

 

Date of the transaction

 

16 December 2021

f)

 

Place of the transaction

 

London Stock Exchange

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Sir Michael Bunbury

2

 

Reason for the notification

 

a)

 

Position/status

 

 Non-Executive Director and Senior Independent Director (SID)

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each



Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




1 19.00p

40,000.00


d)

 

Aggregated information




- Aggregated volume

N/A single transaction



- Price

£47,600.00



e)

 

Date of the transaction

 

16 December 2021

f)

 

Place of the transaction

 

London Stock Exchange

For further information please contact:
Derringtons Limited, Company Secretary
+44 20 8819 6486

 

Ends.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDQLFFFLLXFBQ
UK 100

Latest directors dealings